SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric ETV6-RUNX1 B-Acute Lymphoblastic Leukemia Patients. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.